(Q27649303)

5

0 references

Stefan Knapp

object named as

Stefan Knapp

9

0 references

author name string

Brian Marsden

2

0 references

Vanda Pogacic

3

0 references

Peter Rellos

4

0 references

Alex N Bullock

6

0 references

Juerg Schwaller

7

0 references

Michael Sundström

Proceedings of the National Academy of Sciences of the United States of America

8

0 references

language of work or name

English

0 references

publication date

18 December 2007

0 references

published in

0 references

volume

104

0 references

page(s)

20523-8

0 references

issue

51

0 references

cites work

The selectivity of protein kinase inhibitors: a further update

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2154464

Structural analysis identifies imidazo[1,2-b]pyridazines as PIM kinase inhibitors with in vitro antileukemic activity

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2154464

Structure and regulation of the human Nek2 centrosomal kinase

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2154464

Trans-activation of the DNA-damage signalling protein kinase Chk2 by T-loop exchange

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2154464

Structural characterization of the GSK-3beta active site using selective and non-selective ATP-mimetic inhibitors

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2154464

The protein kinase complement of the human genome

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2154464

Structural basis for inhibition of the cyclin-dependent kinase Cdk6 by the tumour suppressor p16INK4a

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2154464

Multiple modes of ligand recognition: crystal structures of cyclin-dependent protein kinase 2 in complex with ATP and two inhibitors, olomoucine and isopentenyladenine

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2154464

Current development of mTOR inhibitors as anticancer agents

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2154464

Protein kinase C (PKC) family in cancer progression

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2154464

Specificity and mechanism of action of some commonly used protein kinase inhibitors

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2154464

Rational design of inhibitors that bind to inactive kinase conformations

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2154464

A small molecule-kinase interaction map for clinical kinase inhibitors

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2154464

Can the pharmaceutical industry reduce attrition rates?

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2154464

Protein kinases--the major drug targets of the twenty-first century?

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2154464

The specificities of protein kinase inhibitors: an update

7 April 2017

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.0708800104

22 April 2017

New uses for old drugs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2154464

Chemical screening methods to identify ligands that promote protein stability, protein crystallization, and structure determination

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2154464

Drugs, their targets and the nature and number of drug targets

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2154464

Frequent alterations in the expression of serine/threonine kinases in human cancers

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2154464

Treatment of chronic myeloid leukemia with imatinib mesylate

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2154464

Targeting the ERK signaling pathway in cancer therapy

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2154464

Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2154464

Structural basis of inhibitor specificity of the human protooncogene proviral insertion site in moloney murine leukemia virus (PIM-1) kinase

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2154464

The in vitro and in vivo effects of JNJ-7706621: a dual inhibitor of cyclin-dependent kinases and aurora kinases

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2154464

High affinity targets of protein kinase inhibitors have similar residues at the positions energetically important for binding

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2154464

Kinomics: characterizing the therapeutically validated kinase space.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2154464

Kinomics-structural biology and chemogenomics of kinase inhibitors and targets

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2154464

Overexpression of the oncogenic kinase Pim-1 leads to genomic instability.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2154464

Kinetic and catalytic mechanisms of protein kinases

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2154464

The protein kinase activity modulation sites: mechanisms for cellular regulation - targets for therapeutic intervention

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2154464

MEK inhibitors: the chemistry and biological activity of U0126, its analogs, and cyclization products

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2154464

Ligand binding affinity determined by temperature-dependent circular dichroism: cyclin-dependent kinase 2 inhibitors

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2154464

Characterization of a conserved structural determinant controlling protein kinase sensitivity to selective inhibitors.

2 June 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.0708800104

Effect of construct design on MAPKAP kinase-2 activity, thermodynamic stability and ligand-binding affinity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.0708800104

Thermal denaturation: a method to rank slow binding, high-affinity P38alpha MAP kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.0708800104

Synthesis and MEK1 inhibitory activities of imido-substituted 2-chloro-1,4-naphthoquinones

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.0708800104

(S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H)-d ione (LY333531) and related analogues: isozyme selective inhibitors of protein kinase C beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.0708800104

Targeting PIM kinases impairs survival of hematopoietic cells transformed by kinase inhibitor-sensitive and kinase inhibitor-resistant forms of Fms-like tyrosine kinase 3 and BCR/ABL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.0708800104

Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.0708800104

Expression of PKC-beta or cyclin D2 predicts for inferior survival in diffuse large B-cell lymphoma

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18077363

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Do aligned sequences share the same fold?

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18077363